Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-13
2006-06-13
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S002600, C514S018700, C514S019300, C514S020800, C530S331000, C530S345000, C530S409000, C546S045000
Reexamination Certificate
active
07060708
ABSTRACT:
The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.
REFERENCES:
patent: 3843696 (1974-10-01), Wagner et al.
patent: 3846399 (1974-11-01), Hirschmann et al.
patent: 3878187 (1975-04-01), Schneider et al.
patent: 3884898 (1975-05-01), Schneider
patent: 3975342 (1976-08-01), Gross
patent: 3998799 (1976-12-01), Bodor et al.
patent: 4025501 (1977-05-01), Leute
patent: 4040907 (1977-08-01), Ullman et al.
patent: 4297346 (1981-10-01), Rips et al.
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 4457907 (1984-07-01), Porter
patent: 4552864 (1985-11-01), Antoni et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5183883 (1993-02-01), Tanaka et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5610283 (1997-03-01), Buechler
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5767227 (1998-06-01), Latham et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851536 (1998-12-01), Yager et al.
patent: 5882645 (1999-03-01), Toth et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5898033 (1999-04-01), Swadesh et al.
patent: 5910569 (1999-06-01), Latham et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5952294 (1999-09-01), Lazo et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6043230 (2000-03-01), Arimilli et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6074659 (2000-06-01), Kunz et al.
patent: 6093391 (2000-07-01), Kabanov et al.
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6458842 (2002-10-01), Dickinson et al.
patent: 6716452 (2004-04-01), Piccariello et al.
patent: 6740641 (2004-05-01), Gao
patent: 6784186 (2004-08-01), Jackson et al.
patent: 2001/0031873 (2001-10-01), Greenwald et al.
patent: 2002/0098999 (2002-07-01), Gallop et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0151526 (2002-10-01), Gallop et al.
patent: 2002/0151529 (2002-10-01), Cundy et al.
patent: 2004/0204434 (2004-10-01), Shafer et al.
patent: 0 187 547 (1987-07-01), None
patent: WO 94/11021 (1994-05-01), None
patent: WO 95/12605 (1995-05-01), None
patent: WO 95/14033 (1995-05-01), None
patent: WO 97/36616 (1997-10-01), None
patent: WO 98/04277 (1998-02-01), None
patent: WO 00/37103 (2000-06-01), None
patent: WO 02/34237 (2002-05-01), None
Hussain et al. Synthesis and Structural Elucidation of Lipophilic Azidothymidine Conjugates. Liebigs Ann. Chem. 1992, pp. 169-171.
Matsumoto et al. ‘Double-Drugs’—A New Class of Prodrug . . . Bioorganic & Medicinal Chemistry Letters. 2000. vol. 10, pp. 1227-1231.
Supplementary European Search Report for EP 01273387 dated Sep. 28, 2004.
Hosztafi, S. et al. “Synthesis and Analgesic Activity of Nicotinic Esters of Morphine Derivatives,” Arzneim-Forsch./Drug Res. 43(II), Nr. 11 (1993).
International Search Report, dated Oct. 9, 2003, for PCT/US03/05525.
International Search Report, dated Sep. 3, 2003.
Canaris, G., “The Colorado Thyroid Disease Prevalence Study,” Archives Internal Medicine Articles and Abstracts, vol. 160, No. 4 (2000).
Bunevicius, R., “Effects of Thyroxine as Compared with Thyroxine Plus Triiodothyronine in Patients with Hypothyroidism,”The New England Journal of Medicine,vol. 340, No. 6 (1999).
Toft, A., “Thyroid Hormone Replacement—One Hormone or Two?,”The New England Journal of Medicine,vol. 340, No. 6 (1999).
Pade, V., et al., “Link Between Drug Absorption Solubility and Permeability Measurements in Caco-2 Cells,”Journal of Pharmaceutical Sciences,vol. 87, No. 12 (1998).
Oh, D., et al., “Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model,”Pharmaceutical Research,vol. 10, No. 2 (1993).
Amidon, G., et al., “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability,”Pharmaceutical Research,vol. 12, No. 3 (1995).
Presentation to Knoll Pharmaceutical, Apr. 10, 2000.
Investment Banking Presentation, Mar. 27-31, 2000.
Pharma Presentation, Mar. 27-31, 2000, New York, NY.
Deutsch Banc Alex Brown 2000 Health Care Conference Presentation, May 10, 2000, Baltimore, MD.
Apr. 7, 2000, Letter to Credit Suisse First Boston Corporation.
Apr. 7, 2000, Letter to Chase, Hambrecht and Quist.
Apr. 7, 2000, Letter to Banc of America Securities, LLC.
Apr. 7, 2000, Letter to Johnson & Johnson.
Apr. 7, 2000, Letter to AstraZeneca LP.
Apr. 7, 2000, Letters to Bear, Stearns & Company, Inc.
Bankers Presentation, Mar. 27-31, 2000.
Pharmaceutical Presentation, Mar. 27-31, 2000.
KPMG Auditors' Report, Mar. 12, 1999.
Final Report, Study Completion Date Jun. 25, 1998.
Deutsche Banc Alex Brown 2000 Health Care Conference Presentation, May 10, 2000, Baltimore, MD.
Investment Banking (short) Presentation, Apr. 27, 2000.
Investment Banking (long) Presentation, Apr. 27, 2000.
Banc of America Presentation (Not dated).
Pharma Presentation, Apr. 2000.
AstraZeneca Presentation (Not dated).
“Promise of Polythroid,” Presentation, Mar. 2000.
“Introducing Polythroid,” Presentation, Mar. 2000.
Investment Banking Presentation (Not dated).
Pharma Presentation, Mar.-Apr. (Year not given).
Deutsche Banc Alex Brown 2000.
Aug. 31, 1999 Presentation to Scios, Inc.
Feb. 2000 Presentation to Andrx.
Mar. 15, 2000 Presentation to BASF.
Original Presentation to BASF (Not dated).
Feb. 10, 2000 Lotus Presentation.
Okada, Masahiko, et al., “Synthesis of Glycopeptide-conjugates via Ring-Opening Polymerization of Sugar-Substituted α-Amino Acid N-Carboxyanhydrides (GlycoNCAs),”Proc. Japan Acad.,73:205-209 (1997).
Kovacs, J., et al., “Glutamic and Aspartic Anhydrides. Rearrangement of N-Carboxyglutamic 1,5-Anhydride to the Leuchs' Anhydride and Conversion of the Latter to Pyroglutamic Acid,” 85:1839-1844 (Jun. 20, 1963).
Orten, James M. et al., “Thyroxine,”Human Biochemistry,9thEd., C.V. Mosby Company, St. Louis, pp. 401-405 (1975).
Li, Chun, et al., “Complete Regression of Well-Established Tumors Using a Novel Water-Soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate,”Cancer Res,58:2404-2409 (1998).
Kramer, Werner et al., “Intestinal Absorption of Peptides by Coupling to Bile Acids,”The Journal of Biochemistry,269(14); 10621-10627 (1994).
Rawitch, Allen B., et al., “The Isolation of Identical Thyroxine Containing Amino Acid Sequences from Bovine, Ovine and Porcine Thyroglobulins,”Biochemical and Biophysical Research Communications,118(2):423-429 (1984).
Marrio, Claudine, et al., “Amino Acid Sequence of the Unique 3,5,3′-Triiodothyronine-Containing Sequence from Porcine Thyroglobulin,”Biochemical and Biophysical Research Communications,112(1):206-213 (1983).
Sawada, Kyoko, et al., “Recognition of L-Amino Acid Ester Compounds by Rat Peptide Transporters PEPT1 and PEPT2,”Journal of Pharmacology and Experimental Therapeutics,291(2):705-709 (1999).
De Vrueh, Remco L.A., et al, “Transport of L-Valine-Acyclovir Via the Oligopeptide Transporter in the Human Intestin
Kirk Randal J.
Mickle Travis
Piccariello Thomas
Hunton & Williams LLP
New River Pharmaceuticals Inc.
Russel Jeffrey Edwin
LandOfFree
Active agent delivery systems and methods for protecting and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Active agent delivery systems and methods for protecting and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Active agent delivery systems and methods for protecting and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3637227